Navigation Links
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
Date:12/13/2008

HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ -- Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.

HER2+ patients are commonly identified as high risk, yet MammaPrint was able to identify a low risk subgroup of HER2+ patients, who subsequently experienced a 10 year disease-free survival of close to 90 percent even in the absence of (neo)adjuvant trastuzumab (Herceptin(R)) and chemotherapy. Additionally, in a subgroup of highly endocrine responsive HER2/NEU positive patients, MammaPrint(R) low risk patients had no relapse.

The results were presented by Dr. Michael Knauer during the 2008 San Antonio Breast Cancer Symposium (SABCS). In the study population of 169 HER2+ patients MammaPrint(R) classified 16 percent of patients as having a good prognosis signature with a 10-year distant disease-free survival (DDFS) of 89 percent, compared to 84 percent of patients classified as having a poor prognosis signature with a DDFS of 64 percent.

MammaPrint(R)'s robustness is underscored by the 70 gene panel unique to the test and a resulting gene profile that covers all molecular pathways associated with breast cancer. HER2/NEU-overexpression is observed in 15-20 percent of invasive breast cancers and is widely considered to be a negative prognostic factor. As a result, current treatment guidelines classify all HER2-positive breast cancer patients at high risk of relapse, and recommend trastuzumab and chemotherapy.

MammaPrint(R) accurately identified a subgroup of patients with a good clinical outcome in HER2+ early breast cancer. These patients will be further studied in the ongoing MINDACT-trial (Microarra
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
5. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
6. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
7. New Breast Imaging Technology Targets Hard-to-Detect Cancers
8. New Mammography Technology Effective in Detecting Breast Cancer
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
(Date:8/27/2015)... Ohio , Aug. 27, 2015  A mere ... to Booz Allen Hamilton . A new ... product development inefficiencies are impeding and disrupting manufacturers, success. ... Cut Waste and Improve Value In Product Development Processes ... of inaccessible data and how it affects the product ...
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... June 20, 2011 Inogen has been honored with ... Inogen One Portable Oxygen Concentrator.  The Medical Design Excellence ... recognizes contributions and advances in the design of medical ... Goleta, California based Inogen, Inc. is used to provide ...
... approximately 50 million unnecessary visits to primary care physicians ... with increased self-care, including the safe and effective use ... analysis of health management options. These findings—along with a ... of the launch of Your Health at Hand, ...
Cached Medicine Technology:Inogen One Wins Gold Medical Design Excellence Award 2Research Finds Greater Focus on Self-Care Would Save Patients and U.S. Healthcare System Over $5 Billion Annually 2Research Finds Greater Focus on Self-Care Would Save Patients and U.S. Healthcare System Over $5 Billion Annually 3Research Finds Greater Focus on Self-Care Would Save Patients and U.S. Healthcare System Over $5 Billion Annually 4
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Susan ... edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and child ... a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells so ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch ... to having twelve offices in three counties, LA, Orange and San Bernardino. ... region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... California including Los Angeles, Riverside, San Bernardino, and Orange County. , ... executive physical exams are offered annually at all of its locations. Executive ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... today that they have launched their new corporate website http://www.Z-Medica.com , to ... a product-focused website that was launched last year. , “We launched a ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Healthpointe Now Offering Executive Physicals 2Health News:Z-Medica® Launches New Corporate Website 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... Administration (FDA) approved a gel that promises less ... FDA had initially rejected Lifecore Biomedical Inc.'s Intergel, ... gynecologic operations. // ,The gel, formally ... to reduce adhesions, internal scar tissue that can ...
... protein released by damaged heart tissue may be a helpful ... Performing heart bypass surgery or angioplasty on patients with elevated ... estimated 40 percent. ,// ,"Any sign of heart ... amount, was a sign that the patient was at high ...
... it shows that warfarin and aspirin are equally effective in ... prevents blood clotting by stopping platelets from clumping together, while ... both are known to help prevent blood clots in the ... thought that warfarin is more effective at preventing stroke, but ...
... has a similar impact on the body to the ... chronic disorders such as heart disease and diabetes, researchers ... people spend asleep per night in more developed countries ... change has been made to accommodate increased demands of ...
... time, the US Food and Drug Administration (FDA) has approved ... by New Jersey-based Johnson & Johnson, is a one-and-three-quarter-inch patch ... an alternative to birth control pills. // ,The ... period. Ortho Evra can be worn on the lower abdomen, ...
... found a way of creating brain cells out of bone ... Parkinson's disease. At the Peterson Medical College scientists grew stem ... growth factors and other chemicals and found they could get ... cells form muscle, bone, cartilage and fat. The researchers say ...
Cached Medicine News:Health News:Deprived sleep leads to ageing 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: